What is JBIO's stock-based comp?

JBIO (JBIO) reported stock-based comp of $7.41M in Q1 2026.

How has JBIO's stock-based comp changed year-over-year?

JBIO's stock-based comp increased by 205.6% year-over-year, from $2.42M to $7.41M.

What is the long-term trend for JBIO's stock-based comp?

Over 4 years (2021 to 2025), JBIO's stock-based comp has grown at a 76.9% compound annual growth rate (CAGR), from $2.04M to $20.01M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

JBIO JBIO Stock-Based Comp

Stock-Based Comp at other companies

Vertex PharmaceuticalsVRTX

$166.4M+0.2%

Travere Therapeutics, Inc.TVTX

$16.15M+40.5%

Vera TherapeuticsVERA

$13.21M+70.6%

AnaptysBio, Inc.ANAB

$14.22M+55.0%

Avalo TherapeuticsAVTX

$3.58M+10.3%

Cullinan Therapeutics, Inc.CGEM

$7.62M-18.8%

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's stock-based comp?: JBIO (JBIO) reported stock-based comp of $7.41M in Q1 2026.
How has JBIO's stock-based comp changed year-over-year?: JBIO's stock-based comp increased by 205.6% year-over-year, from $2.42M to $7.41M.
What is the long-term trend for JBIO's stock-based comp?: Over 4 years (2021 to 2025), JBIO's stock-based comp has grown at a 76.9% compound annual growth rate (CAGR), from $2.04M to $20.01M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.